参考文献/References:
[1] Molthoff CF,Klabbers BM,Berkhof J,et al.Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice:comparison of 2’-deoxy-2’-[18F]fluoro-D-glucose (FDG)and 3’-[18F]fluoro-3’-deoxythymidine(FLT).Mol Imaging Biol,2007,9(6):340-347.
[2] Agool A,Slart RH,Thorp KK,et al.Effect of radiotherapy and chemotherapy on bone marrow activity:a 18F-FLT-PET study.Nucl Med Commun,2011,32(1):17-22.
[3] Yue J,Chen L,Cabrera AR,et al.Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma:a pilot clinical study.J Nucl Med,2010,51(4):528-534.
[4] Mends Y,Laura L,Dornfeld K,et al.Kinetic analysis of 3’-deoxy-3’-18F-fluorothymidine (18F-FLT)in head and neck cancer patients before and early after initiation of chemoradiation therapy.J Nucl Med,2009,50(7):1028-1035.
[5] Song SL,Liu JJ,Huang G,et al.Changes in 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model.J Nucl Med,2008,49(2):303-309.
[6] Brepoels L,Stroobants S,Verhoef G,et al.18F-FDG and 18F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.J Nucl Med,2009,50(7):1102-1109.
[7] Dose SJ,Bader M,Jenicke L,et al.Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.J Nucl Med,2005,46(7):1144-1150.
[8] Benz MR,Evilevitch V,Allen-Auerbach MS,et al.Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas:interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors.J Nucl Med,2008,49(7):1038-1046.
[9] Sugiyama M,Sakahara H,Sato K,et al.Evaluation of 3’-deoxy-3-18F-Fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice.J Nucl Med,2004,45(10):1754-1758.
[10] Waldherr C,Mellinghoff IK,Tran C,et al.Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3’-deoxy-3’-18F-fluorothymidine PET.J Nucl Med,2005,46(1):114-120.
[11] Oyama N,Ponde DE,Dence C,et al.Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation.J Nucl Med,2004,45(3):519-525.
[12] Pan MH,Huang SC,Lian YP,et al.FLT-PET imaging of radiation responses in mourine tumors.Mol Imaging Biol,2008,10(6):325-334.
[13] Shields AF,Grierson JR,Dohmen BM,et al.Imaging proliferation in vivo with[F-18] FLT and positron emission tomography.Nat Med,1998,4(11):1334-1336.
[14] Turcotte E,Wiens LW,Grierson JR,et al.Toxicology evaluation of radiotracer doses of 3’-deoxy-3’-[18F]fluorothymidine (18F-FLT)for human PET imaging:Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT deses.BMC Nucl Med,2007,7:3.
[15] Waarde AV,Cobben DCP,Suurmeijer AJH,et al.Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.J Nucl Med,2004,45(4):695-700.
[16] Rasey JS,Grierson JR,Wiens LW,et al.Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.J Nucl Med,2002,43(9):1210-1217.
[17] Direcks WG,Bemdsen SC,Proost N,et al.[18F]FDG and[18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy:an in vitro study.Br J Cancer,2008,99(3):481-487.
[18] Wang H,Liu B,Tian JH,et al.Monitoring early responses to irradiation with dual-tracer micro-PET in dual-tumor bearing mice.World J Gastroenterol,2010,16(43):5416-5423.
[19] Withers HR,Taylor JM,Maciejewski B.The hazard of accelerated tumor clonogen repopulation during radiotherapy.Acta Oncol,1988,27(2):131-146.
[20] Langen AJ,Klabbers B,Lubberink M,et al.Reproducibility of quantitative 18F-3’-deoxy-3’-fluorothymidine measurements using positron emission tomography.Eur J Nucl Med Mol Imaging,2009,36(3):389-395.
[21] Muzi M,Mankoff DA,Grierson JR,et al.Kinetic modeling of 3’-deoxy-3’-fluorothymidine in somatic tumors:mathematical studies.J Nucl Med,2005,46(2):371-380.
[22] Muzi M,Vesselle H,Grierson JR,et al.Kinetic analysis of 3’-deoxy-3’-fluorothymidine PET studies:validation studies in patients with lung cancer.J Nucl Med,2005,46(2):274-282.
[23] Muzi M,Spence AM,Sullivan F,et al.Kinetic analysis of 3’-deoxy-3’-18F-fluorothymidinein patients with gliomas.J Nucl Med,2006,47(10):1612-1621.
[24] Buck AK,Halter G,Schirrmeister H,et al.Imaging proliferation in lung tumors with PET:18F-FLT versus 18F-FDG.J Nucl Med,2003,44(9):1426-1431.
[25] Cobben DC,van der Laan BF,Maas B,et al.18F-FLT PET for visualization of laryngeal cancer.comparison with 18F-FDG PET.J Nucl Med,2004,45(2):226-231.
[26] van Westreenen HL,Cobben DC,Jager PL,et al.Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.J Nucl Med,2005,46(3):400-404.
[27] Leyton J,Latigo JR,Perumal M,et al.Early detection of tumor response to chemotherapy by 3’-deoxy-3’-[18F]fluorothymidine positron emission tomography:the effect ofcisplatin on a fibrosarcomatumor model in vivo.Cancer Res,2005,65(10):4202-4210.
[28] Jensen MM,Erichsen KD,Bjorkling F,et al.Early detection of response to experimental chemotherapeutic Top216 with[18F]FLT and[18F]FDG PET in human ovary cancer xenografts in mice.PLoS ONE,2010,5(9):e12965.
[29] Apisarnthanarax S,Alauddin MM,Mourtada F,et al.Early detection of chemoradioresponse in esophageal carcinoma by 3’-deoxy-3’-3H-fluorothymidine using preclinical tumor models.Clin Cancer Res,2006,12(15):4590-4597.
[30] Wang H,Zhang JM,Tian JH,et al.Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.J Nucl Med,2009,50(11):1857-1864.
[31] Troost EG,Bussink J,Aswin L,et al.18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors.J Nucl Med,2010,51(6):866-874.
[32] Dittmann H,Dohmen BM,Paulsen F,et al.[18F]FLT PET for diagnosis and staging of thoracic tumours.Eur J Nucl Med Mol Imaging,2003,30(10):1407-1412.
[33] Chert W,Cloughesy T,Kamdar N,et al.Imaging proliferation in brain tumors with 18F-FLT PET:comparison with 18F-FDG.J Nucl Med,2005,46(6):945-952.
[34] Ecke F,Herrmann K,Schmidt S,et al.Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.J Nucl Med,2009,50(9):1441-1447.
[35] Tian JH,Yang XF,Yu LJ,et al.A Multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3-deoxy-3-18F-fluorothymidine and 18F-FDG.J Nucl Med,2008,49(2):186-194.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[4]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[5]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[6]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[7]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[8]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[9]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[10]许靖,李肖红,秦永德,等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志,2016,40(5):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
Xu Jing,Li Xiaohong,Qin Yongde,et al.Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
[11]刘春利,李毅红.18F-FDG PET/CT在原发灶不明的脑转移瘤中的诊断价值[J].国际放射医学核医学杂志,2013,37(2):92.[doi:10.3760/cma.j.issn.1673-4114.2013.02.008]
LIU Chun-li,LI Yi-hong.The value of 18F-FDG PET/CT in diagnosing brain metastases from unknown primary tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):92.[doi:10.3760/cma.j.issn.1673-4114.2013.02.008]
[12]王胜军,杨卫东,赵小虎,等.18F-FDG PET/CT诊断多发癌的价值[J].国际放射医学核医学杂志,2013,37(2):96.[doi:10.3760/cma.j.issn.1673-4114.2013.02.009]
WANG Sheng-jun,YANG Wei-dong,ZHAO Xiao-hu,et al.Value of 18F-FDG PET/CT in the diagnosis of multiple primary malignant neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):96.[doi:10.3760/cma.j.issn.1673-4114.2013.02.009]
[13]王玉婷,黄钢,蒋瑾,等.18F-FDG PET用于肿瘤治疗疗效评价的meta分析进展[J].国际放射医学核医学杂志,2012,36(6):334.[doi:10.3760/cma.j.issn.1673-4114.2012.06.004]
WANG Yu-ting,HUANG Gang,JIANG Jin,et al.Tumor response monitoring by 18F-FDG PET: updated review of meta-analyses[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):334.[doi:10.3760/cma.j.issn.1673-4114.2012.06.004]
[14]江茂情,吴华.18F-FDG和18F-FLT PET-CT在肿瘤非手术治疗早期疗效评价中的应用[J].国际放射医学核医学杂志,2012,36(6):339.[doi:10.3760/cma.j.issn.1673-4114.2012.06.005]
JIANG Mao-qing,WU Hua.18F-FDG and 18F-FLT PET-CT in evaluation of the early response of malignant tumors after different therapies[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):339.[doi:10.3760/cma.j.issn.1673-4114.2012.06.005]
[15]周敏,魏秋霞,林俊杰,等.良恶性肿瘤18F-FDG符合线路显像的临床价值[J].国际放射医学核医学杂志,2011,35(5):279.[doi:10.3760/cma.j.issn.1673-4114.2011.05.006]
ZHOU Min,WEI Qiu-xia,LIN Jun-jie,et al.18F-FDG coincidence imaging for the detection of benign and malignant neoplasm[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):279.[doi:10.3760/cma.j.issn.1673-4114.2011.05.006]
[16]张慧玮,赵军.18F-FDG代谢显像相关分子机制的研究进展[J].国际放射医学核医学杂志,2011,35(1):1.[doi:10.3760/cma.j.issn.1673-4114.2011.01.001]
ZHANG Hui-wei,ZHAO Jun.Progress of molecular mechanism of 18F-FDG metabolism imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):1.[doi:10.3760/cma.j.issn.1673-4114.2011.01.001]
[17]李亚军,张慧娟.放射性核素标记胆碱与18F-FDG PET肿瘤显像的对比研究[J].国际放射医学核医学杂志,2010,34(6):348.[doi:10.3760/cma.j.issn.1673-4114,2010.06.007]
LI Ya-jun,ZHANG Hui-juan.Comparison choline with 18F-FDG PET in various tumors imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):348.[doi:10.3760/cma.j.issn.1673-4114,2010.06.007]
[18]李红梅,冯珏,李晓东,等.18F-FLT对恶性肿瘤治疗效果的评估价值[J].国际放射医学核医学杂志,2009,33(3):136.[doi:10.3760/cma.j.issn.1673-4114.2009.03.003]
LI Hong-mei,FENG Jue,LI Xiao-dong,et al.The value of 18F-fluorothymidine to monitor the therapeutic effect of malignant tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):136.[doi:10.3760/cma.j.issn.1673-4114.2009.03.003]
[19]司宏伟,徐慧琴,岳峤,等.肿瘤组织乏氧与葡萄糖代谢[J].国际放射医学核医学杂志,2009,33(4):200.[doi:10.3760/cma.j.issn.1673-4114.2009.04.003]
SI Hong-wei,XU Hui-qin,YUE Qiao,et al.Hypoxia and glycometabolism in cancer tissue[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):200.[doi:10.3760/cma.j.issn.1673-4114.2009.04.003]
[20]陈香,赵晋华.PET及PET-CT在监测肿瘤治疗效果中的价值[J].国际放射医学核医学杂志,2007,31(6):354.
CHEN Xiang,ZHAO Jin-hua.Value of PET and PET-CT for monitoring tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):354.